Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate

Journal of Autoimmunity

Volumn 37, Issue 3, 2011, Pages 228-241

  Aharoni, Rina ^a   Vainshtein, Anya ^a   Stock, Ariel ^a   Eilam, Raya ^a   From, Renana ^a   Shinder, Vera ^a   Arnon, Ruth ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Axonal damage; Experimental autoimmune encephalomyelitis (EAE); Glatiramer acetate (GA); Motor neuron loss; Multiple sclerosis (MS); Remyelination

Indexed keywords

GLATIRAMER; MYELIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; MOTONEURON; MOUSE; NERVE FIBER; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELAPSE; REMYELINIZATION;

ANIMALS; AXONS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; MOTOR NEURONS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELIN PROTEINS; MYELIN PROTEOLIPID PROTEIN; MYELIN SHEATH; MYELIN-ASSOCIATED GLYCOPROTEIN; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; PEPTIDES; SPINAL CORD;

EID: 80755139618     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2011.06.003     Document Type: Article

References (50)

1. Lassmann H., Bruck W., Lucchinetti F. The immunopathology of MS: an overview. Brain Pathol 2007, 17:210-218.
2. Lassmann H. Mechanisms of Inflammation induced tissue injury in multiple sclerosis. J Neurol Sci 2008, 274:45-47.
3. Holmoy T. The immunology of multiple sclerosis: disease mechanisms and therapeutic targets. Minerva Med 2008, 99:119-140.
4. Hemmer B., Nessler S., Zhou D., Kieseier B., Hartung H.P. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol 2006, 2:201-211.
5. Frischer J.M., Bramow S., Dal-Bianco A., Lucchietti C.F., Rauschka H., Schmidbauer M., et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-1189.
6. Trapp B.D., Nave K.A. Multiple Sclerosis an immune or neurodegenerative disease. Annu Rev Neurosci 2008, 31:247-269.
7. Bruck W. Evidence for primary neurodegeneration in MS. Mult Scler 2008, 9-13. Supp1.
8. Herz J., Zipp F., Siffrin V. Neurodegeneration in autoimmune CNS inflammation. Exp Neurol 2009, 225:9-17.
9. Geurts J.J., Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol 2008, 7:841-851.
10. Furlan R., Cuomo C., Martino G. Animal models of multiple sclerosis. Methods Mol Biol 2009, 549:157-173.
11. Linker R.A., De-Hyung L. Models of autoimmune demyelination in the central nervous system: on the way to translational medicine. Exp Transl Stroke Med 2009, 1:1-10.
12. Herrero-Herranz E., Pardo L.A., Gold R., Linker R.A. Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol Dis 2008, 30:162-173.
13. Bannerman P.G., Hahn A., Morley M., Bonnemann C., Yu S., Zhang G.X., et al. Motor neuron pathology in experimental autoimmune encephalomyelitis: studies in THY-YFP transgenic mice. Brain 2005, 128:1877-1886.
14. Huizinga R., Gerritsen W., Heijmans N., Amor S. Axonal loss and gray matter pathology as a direct result of autoimmunity to neurofilaments. Neurobiol Dis 2008, 32:461-470.
15. Voget J., Paul F., Aktas O., Muller-Wielsch K., Dorr J., Dorr S., et al. Lower motor neuron loss in multiple sclerosis and experimental autoimmue encephalomyelitis. Ann Neurol 2009, 66:310-322.
16. Hampton D.W., Anderson J., Pryce G., Irvine K.-A., Giovannoni G., Fawcett J.W., et al. An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination axonal and neuronal loss. J Neuroimmunol 2008, 201:200-211.
17. Giardino L., Giuliani A., Fernandez M., Calza L. Spinal motoneurone distress during experimental allergic encephalomyelitis. Neuropathol Appl Neurobiol 2004, 30:522-531.
18. Aharoni R., Arnon R. Linkage between immunomodulation neuroprotection and neurogeneisis. Drug News Prospect 2009, 22:301-313.
19. Bruck W., Kuhlmann T., Stadelmann C. Remyelination in multiple sclerosis. J Neurol Sci 2003, 206:181-185.
20. Reynolds R., Dawson M., Papadopoulos D., Polito A., Di Bello I.C., Pham-Dinh D., et al. The response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS. J Neurocytol 2002, 31:523-536.
21. Picard-Riera N., Decker L., Delarasse C., Goude K., Nait-Oumesmar B., Liblau R., et al. Experimental autoimmune encephalomyelitis mobilizes neural progenitors from the subventricular zone to undergo oligodendrogenesis in adult mice. Proc Natl Acad Sci USA 2002, 99:13211-13216.
22. Aharoni R. Immunomodulatory drug treatment in multiple sclerosis. Expert Rev Neurother 2010, 10:1423-1436.
23. Teitelbaum D., Meshorer M., Hirshfeld T., Sela M., Arnon R. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971, 1:242-248.
24. Fridkis-Hareli M., Teitelbaum D., Gurevich E., Pecht I., Brautbar C., Kwon O.J., et al. Direct binding of myelin basic protein and synthetic copolymer 1 class II major histocompatibility complex molecules on living antigen presenting cells-specificity and promiscuity. Proc Natl Acad Sci USA 1994, 91:4872-4876.
25. Aharoni R., Teitelbaum D., Arnon R., Sela M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci USA 1999, 96:634-639.
26. Farina C., Weber M.S., Meinl E., Wekerle H., Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 2005, 4:567-575.
27. Weber M.S., Prod'homme T., Youssef S., Dunn S.E., Rundle C.D., Lee L., et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007, 13:935-943.
28. Aharoni R., Teitelbaum D., Sela M., Arnon R. Copolymer 1 induces T cells of the T helper type 2 that cross react with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1997, 94:10821-10826.
29. Neuhaus O., Farina C., Yassouridis A. Multiple sclerosis comparison of copolymer-1 reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA 2000, 97:7452-7457.
30. Aharoni R., Teitelbaum D., Leitner O., Meshorer A., Sela M., Arnon R. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci USA 2000, 97:11472-11477.
31. Aharoni R., Kayhan B., Eilam R., Sela M., Arnon R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Nat Acad Sci USA 2003, 100:14157-14162.
32. Begum-Haque S., Sharma A., Kasper I., Foureau D.M., Mielcarz D.W., Haque A., et al. Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis. J Neuroimmunol 2008, 204:58-65.
33. Aharoni R., Eilam R., Stock A., Vainshtein A., Shezen E., Gal H., et al. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE. J Neuroimmunol 2010, 225:100-111.
34. Aharoni R., Eylam R., Domev H., Labunsky G., Sela M., Arnon R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci USA 2005, 102:19045-19050.
35. Azoulay D., Vachapova V., Shihman B., Miler A., Karni A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol 2005, 167:215-218.
36. Aharoni R., Arnon R., Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J Neuroscience 2005, 25:8217-8228.
37. Aharoni R., Herschkovitz A., Eilam R., Blumberg-Hazan M., Sela M., Bruck W., et al. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2008, 105:11358-11363.
38. Feng G., Mellor R.H., Bernstein M., Keller-Peak C., Nguyen Q.T., Wallace M., et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 2000, 28:41-51.
39. Chang H.M., Wei I.H., Tseng C.Y., Lue J.H., Wen C.Y., Shieh J.Y. Differential expression of calcitonin gene-related peptide (CGRP) and choline acetyltransferase (ChAT) in the axotomized motoneurons of normoxic and hypoxic rats. J Chem Neuroanat 2004, 28:239-251.
40. Middeldorp J., Hol E.M. GFAP in health and disease. Prog Neurobiol 2011, 93:421-443.
41. Noraberg J., Kristensen B.W., Zimmer J. Markers for neuronal degeneration in organotypic slice cultures. Brain Res Prot 1999, 3:278-290.
42. Centonze D., Muzio L., Rossi S., Cavasinni F., De Chiara V., Bergami A., et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci 2009, 18:3442-3452.
43. Ziehn M.O., Avedisian A.A., Tiwari-Woodruff S., Voskuhl R.R. Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE. Lab Invest 2010, 90:774-786.
44. Fischer L.R., Culver D.G., Tennant P., Davis A.A., Wang M., Castellano-Sanchez A., et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 2004, 185:232-240.
45. Haramati S., Chapnik E., Sztainberg Y., Eilam R., Zwang R., Gershoni N., et al. miRNA malfunction causes spinal motor neuron disease. Proc Natl Acad Sci USA 2010, 107:13111-13116.
46. Wujek J.R., Bjartmar C., Richer E., Ransohoff R.M., Yu M., Tuohy V.K., et al. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol 2002, 61:23-32.
47. Lessman V., Gottmann K., Malcangio M. Neurotrophin secretion: current facts and future prospect. Prog Neurobiol 2003, 69:341-374.
48. Murer M.G., Yan O., Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prop Neurobiol 2001, 63:71-124.
49. Franklin R.J., Hinks G.L. Understanding CNS remyelination: clues from developmental and regeneration biology. J Neurosci Res 1999, 15:207-213.
50. Lalive P.H., Paglinawan R., Biollaz G., Kappos E.A., Leone D.P., Malipiero U., et al. Eur J Immunol 2005, 35:727-737.